Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Duchenne Muscular Dystrophy

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Infectious Disease

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Nephrology

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

PTSD

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Schizophrenia

Shingles

Skin Cancer

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Uro-Oncology

Urothelial Carcinoma

Vaccines

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

Webinars

CME/CE

Resources

PBMI Innovators

Emerging Leaders

Interactive Tools

PBM Directory

Subscribe

Articles

Illuminate Rx is the country’s first pharmacist-designed pharmacy benefits optimizer (PBO), offering transparent, clinically driven PBM options for brokers and self-funded employers, with a focus on data clarity, flexible formulary design and specialty pharmacy partnerships, according to Robert Gamble, CEO of RxBenefits. 

A Conversation with Robert Gamble, CEO of RxBenefits 

Diagnosed with triple-negative breast cancer at age 36 and now in remission, gynecological oncologist Deanna Gerber, M.D., says her experience has made her a better physician and advocate for her patients.

A Conversation With Deanna Gerber, M.D., Assistant Professor of Obstetrics and Gynecology in the Division of Gynecologic Oncology at Weill Cornell Medicine

A decline in PrEP coverage could reverse HIV prevention gains, causing tens of thousands of preventable infections and billions in added healthcare costs, a new JAMA Network Open study finds.

3.3% Annual Reduction of PrEP Coverage Would Result in Thousands of HIV Infections, Cost Billions 

The new JAMA + Women’s Health multimedia channel focuses on all aspects of women’s health, not just topics like menopause or ovarian cancer, presenting content from across JAMA and JAMA Network in one place. 

JAMA Launches New Channel, JAMA + Women’s Health 

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive - Payer and Population Health Insights

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

ASRS 2025

IAS 2025

AMCP Annual

K-Cast: Optimizing Narcolepsy Care

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Clinical

Roche test could lead to early identification of infections.

Precision Medicine for Hepatitis B: Roche's Elecsys HBeAg Quant Test

There is no vaccine against the hepatitis C virus. A subscription-like payment model may help overcome some of the cost issues posed by direct-acting antivirals.

The Best Hope for Eradicating HCV


If approved, elafibranor would be a second-line treatment for patients with primary biliary cholangitis. The Prescription Drug User Fee Act action date is June 10, 2024.


FDA Sets Review Date for Elafibranor for Rare Liver Disease

The authors found that patients who received DAA treatment had a five-year survival rate of 47.2% compared with 35.2% for untreated patients.

Addressing the Treatment Gap: Improving Antiviral Therapy for HCV-Related Hepatocellular Carcinoma

Researchers from the Centers for Disease Control and Prevention identified 315 deaths from hepatitis A.

Deaths From Hepatitis A: Vaccination Could Prevent Them

Liver Disease

Latest News